**Supplemental Figure Legends**

**Figure S1**: PD-L1 expression in FFPE samples with anti-PD-L1 antibody (clone E1L3N): A) Positive control (HDLM2 cell line with known PD-L1 expression). B) Negative control (PC3 cell line).

**Figure S2:** PD-L1 Immunohistochemical Analysis.Representative images of negative PD-L1 expression (A), ≥1%, <5% PD-L1 expression (B), ≥5%, <50% PD-L1 expression (C) and ≥50% PD-L1 expression (D) on FFPE samples.

**Figure S3:** Immunohistochemical Analysis of CD8+ Tumor Infiltrating Lymphocytes. Representative images of CD8 scoring: 0 (A), 1+ (B), 2+ (C), and 3+ (D).

**Figure S4:** Quantitative image-based CD8+ TILs in baseline specimens of *EGFR*-mutant versus *KRAS*-mutant patients.

**Figure S5**: A-C): Images of autopsy specimens from an ALK-positive NSCLC patient, demonstrating heterogeneous expression of PD-L1 in multiple sections examined (Diffuse PD-L1 expression in A-B and focal PD-L1 expression in C).